New drug takes aim at hard-to-treat neuroendocrine prostate cancer
NCT ID NCT07639086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a drug called sacituzumab tirumotecan in people with neuroendocrine prostate cancer, a rare and aggressive form that has progressed after platinum-based chemotherapy. The drug is given by IV infusion three times per 42-day cycle. The study measures how many patients' tumors shrink or disappear, and how long they live without the cancer worsening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab tirumotecan
What this could lead to
If effective, this drug could offer a new treatment option for a rare and aggressive form of prostate cancer that has stopped responding to chemotherapy.
What could go wrong
This is a small, early-phase trial with only 20 participants. The drug may not shrink tumors or improve survival, and side effects from the infusion are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••